Company: CMND
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001213900-25-117534
Chunk: 10

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 10
---
.

The November 2025 Offering closed on November 13, 2025. The aggregate gross proceeds to the Company were approximately $0.788 million.

Second November 2025 Registered Direct Offering

On November 17, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of (i) 3,991,768 common shares, and (ii) pre-funded warrants to purchase up to 1,518,000 common shares, in a registered direct offering, or the Second November 2025 Offering, at a purchase price of $0.25 per common share and $0.2499 per pre-funded warrant.

The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire until exercised in full.

The Second November 2025 Offering closed on November 17, 2025. The aggregate gross proceeds to the Company were approximately $1.377 million.

On November 19, 2025, we entered
into a securities purchase agreement with investors for the purchase and sale of 10,925,000 common shares, at a purchase price
of $0.20 per common share.

The Third November 2025 Offering
closed on November 20, 2025. The aggregate gross proceeds to the Company were approximately $2.185 million.

<div align='center'>S-3</div>

On November 26, 2025, we entered
into a securities purchase agreement with investors for the purchase and sale of (i) 7,944,868 common shares, and (ii) pre-funded
warrants to purchase up to 2,865,960 common shares, in a registered direct offering, or the Fourth November 2025 Offering, at a purchase
price of $0.12 per common share and $0.1199 per pre-funded warrant.

The pre-funded warrants are
immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire
until exercised in full.

The Fourth November 2025 Offering
closed on November 26, 2025. The aggregate gross proceeds to the Company were approximately $1.294 million.

Warrant Exercises

As of December 2, 2025, investors
from our financings in April 2023 and January 2024 exercised an aggregate of warrants to purchase 2,894